24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment.

Plain-language guide to PMID 18319308 (2008): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 18319308
Journal: The Journal of clinical endocrinology and metabolism
Year: 2008
Study type: Randomized Controlled Trial
Authors: Kalleinen N et al. (7 authors)
DOI: 10.1210/jc.2007-2677

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Their objective was to study the 24-h profiles of GH, prolactin (PRL), and cortisol concentrations in older postmenopausal and middle-aged premenopausal women, before and after estrogen-progestin treatment (EPT).

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

The study was a randomized, placebo-controlled, double-blind trial.

What Was Measured

PubMed files the paper under topics including Estrogen Replacement Therapy, Estrogens, Human Growth Hormone, Hydrocortisone, Postmenopause, Premenopause and Progestins.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.